Complicated skin and soft tissue infections: Literature review of evidence for and experience with daptomycin

Infection and Drug Resistance

Volumn 4, Issue 1, 2011, Pages 115-127

  White, Beth ^a   Seaton, R Andrew ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Lipopeptide; MRSA; OPAT; Outpatient parenteral antibiotic therapy; SSTI

Indexed keywords

DAPTOMYCIN; LINEZOLID; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIUM IDENTIFICATION; BONE MARROW SUPPRESSION; CLINICAL FEATURE; DIABETIC FOOT; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; ENDOCARDITIS; HUMAN; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MITOCHONDRIAL TOXICITY; MYOPATHY; NONHUMAN; PHARMACODYNAMICS; PROTHROMBIN TIME; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL INFECTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84860359452     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S13808     Document Type: Review

References (74)

1. Cubicin summary of product characteristics 2010. Available at: www. emea.europa.eu/humandocs/Humans/EPAR/cubicin/cubicin.htm. Accessed 30 January 2011
2. Beiras-Fernandez A, Vogt F, Sodian R, et al. Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect Drug Resist. 2010;3:95-101.
3. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52 Suppl 1:i3-i17
4. FDA. Guidance for Industry: uncomplicated and complicated skin and skin structure infections-developing antimicrobial drugs for treatment. Available from: http://www.fda.org/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf. Accessed 30 January 2011
5. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol. 2008;19(2):173-184.
6. Marwick C, Broomhall J, McCowan C, et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother. 2011;66(2): 387-397.
7. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections amongst patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
8. European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC;2010. Available from: http://www.ecdc.europa.eu/en/publications/Publications/1011_SUR_annual_EARS_Net_2009.pdf. Accessed 30 January 2011
9. Gemmel CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006;57(4): 589-608.
10. Leman P, Mukherjee D. Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: a randomized controlled trial. Emerg Med J. 2005;22(5):342-346.
11. Boucher H, Miller LG, Razonable RR. Serious infections caused by Methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2010; 51 Suppl 2:S183-S197
12. Kinney KK. Treatment of infections caused by antimicrobial-resistant Gram-positive bacteria. Am J Med Sci. 2010;340(3):209-217.
13. Itani KM, Dryden MS, Bhattacharyya, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199(6):804-816.
14. Gould FK, Brindle R, Chadwick PR, et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother. 2009;63(5):849-861.
15. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673-1681.
16. Bliziotis IA, Plessa E, Peppas G, Falagas ME. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: A meta-analysis. Ann Pharmacother. 2010;44(1):97-106.
17. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. Journal of Infection. 2009;59 Suppl 1:S59-S74
18. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. JAntimicrob Chemother. 2004;53(4):669-674.
19. Anastasiou DM, Thorne GM, Luperchio S, Alder JD. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinuprisitn/dalfopristin. Int J Antimicrob Agents. 2006;28(5):385-388.
20. Alborn WE Jr, Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother. 1991;35(11):2282-2287.
21. Hair PI, Keam SJ. Daptomycin: A review of its use in the management of complicated skin and soft tissue infections and Staphylococcus aureus bacteraemia. Drugs. 2007;67(10):1483-1512.
22. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 2002;46(1):31-33.
23. Ritchie ND, Lovering AM, Seaton RA. Daptomycin in synovial fluid during treatment of methicillin-resistant Staphylococcus aureus septic arthritis. J Antimicrob Chemother. 2010;65(6):1314-1315.
24. Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother. 2010;65(6):1252-1257.
25. Schrievner CA, Fernandez C, Rodvold K, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm. 2005; 62(11):1145-1158.
26. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of Methicillin-Resistant Staphylococcus aureus infections in adults and children. Clin Inf Dis. 2011;52(3):e18-e55
27. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteraemia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653-665.
28. US Food and Drug Administration. FDA drug safety communication: eosinophilic pneumonia associated with the use of Cubicin (daptomycin). Available from: www.fda.gov/drugs/drugsafety. Updated 29 July 2010. Accessed 30 January 2011
29. Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved Gram-positive infections. Paediatr Infect Dis J. 2008;27(4):330-334.
30. Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother. 2008;62 Suppl 3: iii15-iii23
31. Johns Hopkins POC-IT Center ABX Guide Home page on the Internet. Available from: http://hopkins-abxguide.org Accessed January 2011
32. Krige JE, Lindfield K, Friedrich L, et al. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin. 2007;23(9):2147-2156.
33. Gollnick H, Quist SR, Fierlbeck G, et al. Efficacy and safety of daptomycin versus vancomycin or teicoplanin for the treatment of cSSTIs: a multicenter, randomised, assessor-blind trial. Abstract of the 20th European Congress of Clinical Microbiology and Infectious Diseases; 2010 April 10-13: Vienna, Austria; Poster 1551
34. Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin versus vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;633(3):368-375.
35. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high dose short duration daptomycin for the treatment of patients with complicated skin and skin-structure infections caused by Gram-positive bacteria. Int J Clinc Pract. 2008;62(9):1455-1464.
36. Davis SL, McKinnon PS, Hall LM, et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy. 2007;27(12):1611-1618.
37. Figtree M, Konecny P, Jennings Z, Goh C, Krikis SA, Miyakis S. Risk stratification and outcome of cellulitis admitted to hospital. J Infect. 2010;60(6):431-439.
38. Logman JFS, Stephens J, Haider S, et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin. 2010;26(7):1565-1578.
39. Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother. 2011;66(4):912-919.
40. Owens RC Jr, Lamp K, Friedrich LV, et al. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med. 2007;120(10 Suppl 1):S6-S12
41. Brown J, Lamp KC, Friedrich L. Efficacy and safety of daptomycin for the treatment of skin and skin structure infections (SSSI). In: Abstracts of the Fourth International Symposium on Resistant Gram-positive Infections, Ontario, Canada, 2006. Abstract CPLA27
42. Katz DE, Martone WJ. cSSTIs with culture confirmed Staphylococcus aureus treated with daptomycin: Cubicin Outcome Registry and Experience (CORE) 2005 Interim Analysis. In: Abstracts of the 2006 Annual Conference on Antimicrobial Resistance; 2006 June 26-28: Bethesda, MD. Poster 22:25. National Foundation for Infectious Diseases, Bethesda, MD
43. Lamp KC, Friedrich L, Lindfield K. Clinical factors associated with daptomycin outcomes in skin and soft-tissue infections. In: Abstracts of the Seventeenth European Congress of Clinical Microbiology and Infectious Diseases; 2007 March 31-April 3: Munich, Germany. Poster 837: S213. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland
44. Cogo A, Dialiana Z, Gargalianos-Kakolyris P et al. Complicated skin and soft tissue infections (cSSTIs) treated with daptomycin in the European Cubicin Outcomes Registry and Experience (EU-CORE). In: Abstracts from the 20th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases); 2010 April 10-13: Vienna, Austria. Poster 1227
45. Rolston KV, Segreti J, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007; 120(10 Suppl 1):S4-S5
46. Sakoulas G, Brown J, Lamp K, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther. 2009;31(9): 1936-1945.
47. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infectionrelated mortality in the US. Diabetes Care. 2001;24(6):1044-1049.
48. Chamberlain RS, Culshaw DL, Donovan BJ, Lamp KC. Daptomycin for the treatment of surgical site infections. Surg. 2009;146(2):316-324.
49. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis. 2007;57(4):459-465.
50. Castanheira M, Jones RN, Sader HS. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). Diagn Microbiol Infect Dis. 2008;61(2):235-239.
51. Sader HS, Farrell DJ, Jones RN. Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centers. Int J Antimicrob Agents. 2010;36(1): 28-32.
52. Sader HS, Moet G, Jones RN. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007). J Chemother. 2009;21(5):500-506.
53. Bell JM, Turnidge JD, Sader HS, Jones RN. Antimicrobial activity and spectrum of daptomcyin: results from the surveillance program in Australia and New Zealand (2008). Pathology. 2010;42(5):470-473.
54. Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). Braz J Infect Dis. 2009;13(2):90-98.
55. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55(2):240-245.
56. Martone WJ, Lindfield KC, Katz DE. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract. 2008;62(8):1183-1187.
57. Seaton RA, Coia J, Masterton R, et al. MRSA complicated skin and skin structure infections in Glasgow: evaluation of hospital management and potential for earlier discharge. In: Abstracts from the 20th European Congress of Clinical Microbiology and Infectious Diseases; 2010 April 10-13: Vienna, Austria. Poster 1873
58. Seaton RA, Bell E, Gourlay Y, Semple L. Nurse-led management of uncomplicated cellulitis in the community; evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother. 2005; 55(5):764-767.
59. Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother. 2009;64(1):181-187.
60. Seaton RA, Bell E, Bezlyak V, et al. Factors associated with outcome and length of parenteral therapy in outpatient parenteral antibiotic therapy (OPAT) treated patients with skin and soft tissue infections (SSTIs). In: Abstracts from the 19th European Congress Clinical Microbiology and Infectious Diseases; 2010 April 10-13: Vienna, Austria. Poster 1333
61. Seaton RA, Gonzalez-Ramallo VJ, Prisco V, et al. Daptomycin for outpatient parenteral antibiotic therapy (OPAT), a European registry experience. In: Abstracts from the 7th International Conference of the Hospital Infection Society; 2010 October 10-13: Liverpool, UK. Poster 01.06
62. Huang Y, Hsiao C, Liao C, Lee CW, Hsueh PR. Bacteraemia and infective endocarditis cuased by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol. 2008;46(3):1132-1136.
63. Hayden MK, Rezai K, Hayes RA, Loland K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43(10):5285-5287.
64. Cui L, Tominaga E, Neoh HM, et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(3):1079-1082.
65. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006;50(4):1581-1585.
66. Sader HS, Becker HK, Moet GJ, Jones RN. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008). Diagn Microbiol Infect Dis. 2010;66(3):329-331.
67. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilising high-dose (8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009;43(7):1211-1219.
68. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteraemia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung. 2006; 35(3):207-211.
69. Lamp KC, Friedrich LV, Medez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007;120(10 Suppl 1):S13-S20
70. Mohr III JF, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD. Pharmacokinetic evaluation of singledose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother. 2008;52(5):1891-1893.
71. Goetghebeur M, Landry PA, Han D, Vicente C. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol. 2007;18(1):27-34.
72. Fossaceca C. Outcomes analysis of daptomycin use in a community hospital. Adv Ther. 2007;24(3):517-528.
73. Nathwani D, Morgan M, Masterton RG. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61(5):976-994.
74. Mensa J, Barberan J, Llinares P, et al. Guidelines for the treatment of infections caused by methicillin-resistant Staphylococcus aureus. Rev Esp Quimioter. 2008;21(4):234-258.